These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21649536)

  • 21. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
    Dejaco C; Duftner C; Wipfler E; Schirmer M
    Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving patient outlook in rheumatoid arthritis: experience with abatacept.
    Coughlin M
    J Am Acad Nurse Pract; 2008 Oct; 20(10):486-95. PubMed ID: 19128344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the use of abatacept for the treatment of rheumatoid arthritis.
    Vicente Rabaneda EF; Herrero-Beaumont G; Castañeda S
    Expert Rev Clin Immunol; 2013 Jul; 9(7):599-621. PubMed ID: 23899231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
    Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC
    J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
    Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
    Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Abatacept].
    Nakamura T; Matsubara T
    Nihon Rinsho; 2013 Jul; 71(7):1232-7. PubMed ID: 23961672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abatacept for rheumatoid arthritis: a Cochrane systematic review.
    Maxwell LJ; Singh JA
    J Rheumatol; 2010 Feb; 37(2):234-45. PubMed ID: 20080922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
    Harigai M
    Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
    Callhoff J; Weiß A; Zink A; Listing J
    Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abatacept treatment for rheumatoid arthritis.
    Schiff M
    Rheumatology (Oxford); 2011 Mar; 50(3):437-49. PubMed ID: 20876701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.